GLP-1 & Metabolic Peptides Research Hub — Mechanisms, Comparisons & Cluster Resource (2026)
GLP-1 & Metabolic Peptides Research Hub — Mechanisms, Comparisons & Complete Cluster Resource (2026)
Document ID: HKPW-PILLAR-2026-002 | Reviewed by: HKPEPTIDE WORLDWIDE Research Team — Dr. A. Chen, PhD (Biochemistry); Dr. M. Kowalski, PhD (Pharmacology); Dr. S. Patel, PhD (Metabolic Biology) | Last Updated: 2026-08-08
Executive Summary
The GLP-1 and metabolic peptide category represents the most transformative area in contemporary peptide research, accounting for the largest share of the $40+ billion global peptide therapeutics market. From the foundational discovery of glucagon-like peptide-1 (GLP-1) in the 1980s to the recent emergence of triple receptor agonists, this field has produced some of the most consequential advances in metabolic biology — reshaping our understanding of energy homeostasis, appetite regulation, and the gut-brain axis.
This hub consolidates the complete HKPEPTIDE WORLDWIDE GLP-1/metabolic research ecosystem. It provides detailed mechanism comparisons across all major incretin and metabolic peptides, a comprehensive receptor target matrix, and individual deep dives into Semaglutide, Tirzepatide, Retatrutide, Cagrilintide, AOD-9604, AICAR, MOTS-c, and NAD+. Every section is grounded in peer-reviewed literature with PMID-cited references, enabling researchers to navigate from fundamental mechanisms to specific product selections with full scientific context.
Related Pillars: Complete Guide to Research Peptides | Peptide Quality Verification Hub | Healing & Regenerative Peptides Hub
1. The Incretin System — Foundational Biology
1.1 Discovery and Physiological Framework
The incretin system comprises gut-derived hormones that potentiate glucose-stimulated insulin secretion from pancreatic β-cells. The two primary incretins are GLP-1 (glucagon-like peptide-1), secreted by intestinal L-cells in response to nutrient ingestion, and GIP (glucose-dependent insulinotropic polypeptide), released from duodenal K-cells. Together, they account for approximately 50–70% of postprandial insulin secretion — a phenomenon known as the “incretin effect” (PMID: 17928588).
Native GLP-1 has an extremely short plasma half-life of approximately 2 minutes due to rapid cleavage by the ubiquitous enzyme DPP-4 (dipeptidyl peptidase-4), which cleaves the N-terminal dipeptide His-Ala, rendering the molecule inactive. This short half-life posed a fundamental challenge that drove decades of medicinal chemistry innovation, culminating in the development of DPP-4-resistant GLP-1 receptor agonists with extended pharmacokinetic profiles.
GLP-1’s physiological actions extend far beyond insulin secretion:
- Pancreatic: Glucose-dependent insulin secretion ↑, glucagon secretion ↓, β-cell proliferation and survival ↑
- Gastric: Gastric emptying ↓, acid secretion ↓
- Central Nervous System: Satiety ↑, food intake ↓, neuroprotection
- Cardiovascular: Heart rate ↑, cardiac contractility ↑, blood pressure ↓, endothelial function ↑
- Hepatic: Gluconeogenesis ↓, steatosis ↓ (indirect via reduced glucagon and body weight)
1.2 The Amylin System — A Complementary Pathway
Amylin (islet amyloid polypeptide, IAPP) is a 37-amino acid peptide co-secreted with insulin from pancreatic β-cells. Like GLP-1, amylin suppresses postprandial glucagon secretion, slows gastric emptying, and promotes satiety — but through distinct receptor mechanisms. Amylin acts through amylin receptors (AMY1-3), which are calcitonin receptor (CTR)/receptor activity-modifying protein (RAMP) complexes, rather than through GLP-1 receptors.
This mechanistic orthogonality — GLP-1R activation vs. amylin receptor activation — provides the rationale for combining GLP-1 agonists with amylin analogs like Cagrilintide. The pathways converge on similar physiological outcomes (satiety, slowed gastric emptying, glucagon suppression) but through independent receptor systems, enabling additive or synergistic effects in research protocols.
1.3 AMPK — The Cellular Energy Sensor
AMP-activated protein kinase (AMPK) functions as the master cellular energy sensor, activated when the AMP:ATP ratio rises (indicating low energy status). AMPK activation triggers catabolic pathways that generate ATP (fatty acid oxidation, glucose uptake, glycolysis) while inhibiting anabolic pathways that consume ATP (protein synthesis, lipogenesis, gluconeogenesis). Multiple metabolic research compounds — including AICAR and MOTS-c — converge on AMPK activation, making it a central node in metabolic peptide research.
2. Mechanism Comparison Table — All GLP-1/Metabolic Compounds
This comprehensive table enables direct comparison of all metabolic research compounds available from HKPEPTIDE WORLDWIDE across key pharmacological parameters.
| Compound | Class | Primary Target(s) | Mechanism | Half-Life (Research) | Key Downstream Effects | MW | Purity |
|---|---|---|---|---|---|---|---|
| Semaglutide | GLP-1RA | GLP-1R | Selective GLP-1R agonism; albumin binding via C18 diacid | ~7 days (albumin-bound) | Insulin ↑, glucagon ↓, gastric emptying ↓, satiety ↑ | 4113.6 Da | ≥99% HPLC |
| Tirzepatide | Dual GIP/GLP-1RA | GIPR > GLP-1R | Unbalanced dual agonism (GIPR-biased); C20 diacid albumin binding | ~5 days | Insulin ↑↑, glucagon ↓↓, body weight ↓↓, insulin sensitivity ↑ | ~4800 Da | ≥99% HPLC |
| Retatrutide | Triple GIP/GLP-1R/GCGR | GIPR, GLP-1R, GCGR | Balanced triple agonism; adds GCGR-mediated energy expenditure | ~6 days | Insulin ↑, glucagon (paradoxical ↑ via GCGR), energy expenditure ↑, lipolysis ↑ | ~5000 Da | ≥99% HPLC |
| Cagrilintide | Amylin Analog | AMY1-3 (CTR/RAMP) | Long-acting amylin receptor agonism | ~7–10 days | Glucagon ↓, gastric emptying ↓↓, satiety ↑ (hindbrain) | ~4100 Da | ≥99% HPLC |
| Cag/Sema Blend | Amylin + GLP-1RA | AMY1-3 + GLP-1R | Dual orthogonal pathway activation | Combined | Synergistic satiety, glucagon suppression, gastric emptying | — | ≥99% HPLC |
| AOD-9604 | hGH Fragment | Lipolytic receptor (FAT/CD36?) | Lipolysis without diabetogenic effects | ~4–6 hours | Lipolysis ↑, fat oxidation ↑, no IGF-1 elevation | ~1800 Da | ≥99% HPLC |
| AICAR | AMPK Activator | AMPK (via ZMP) | Cell-permeable adenosine analog; phosphorylated to ZMP | ~1–2 hours | AMPK activation → glucose uptake ↑, fatty acid oxidation ↑, mitochondrial biogenesis ↑ | 258.2 Da | ≥98% HPLC |
| MOTS-c | Mitochondrial Peptide | Nuclear ARE; AMPK | Mitochondrial-nuclear retrograde signaling; folate cycle regulation | ~4–8 hours | AMPK activation, insulin sensitivity ↑, fatty acid oxidation ↑, folate cycle modulation | 2174.6 Da | ≥98% HPLC |
| NAD+ | Coenzyme | Sirtuins, PARPs, CD38 | Redox coenzyme; sirtuin substrate | ~2–4 hours | SIRT1/3 activation, mitochondrial biogenesis ↑, DNA repair ↑, redox balance | 663.4 Da | ≥98% HPLC |
3. Receptor Target Matrix
This matrix maps each compound to its specific receptor targets and key signaling pathways, enabling researchers to design protocols based on receptor pharmacology profiles.
| Compound | GLP-1R | GIPR | GCGR | AMY1-3 (CTR/RAMP) | AMPK | SIRT1/3 | Nuclear ARE | FAT/CD36 |
|---|---|---|---|---|---|---|---|---|
| Semaglutide | +++ | — | — | — | + (indirect) | — | — | — |
| Tirzepatide | ++ | +++ | — | — | + (indirect) | — | — | — |
| Retatrutide | ++ | ++ | ++ | — | + (indirect) | — | — | — |
| Cagrilintide | — | — | — | +++ | — | — | — | — |
| Cag/Sema Blend | +++ | — | — | +++ | + (indirect) | — | — | — |
| AOD-9604 | — | — | — | — | — | — | — | ++ |
| AICAR | — | — | — | — | +++ | + (AMPK→SIRT1) | — | — |
| MOTS-c | — | — | — | — | +++ | — | +++ | — |
| NAD+ | — | — | — | — | + (SIRT1→AMPK crosstalk) | +++ | — | — |
Key: +++ = Primary/high-affinity target; ++ = Significant secondary target; + = Indirect/weak activation; — = No significant interaction
3.1 Interpretation Notes
The receptor target matrix reveals several important patterns:
- Incretin agonists (Semaglutide, Tirzepatide, Retatrutide) target the G-protein-coupled receptor (GPCR) superfamily, with progressive receptor coverage from single to triple agonism
- Amylin analogs (Cagrilintide) target a completely distinct receptor system, enabling orthogonal pathway research
- AMPK activators (AICAR, MOTS-c) represent a mechanistically distinct approach targeting intracellular energy sensing rather than membrane receptors
- NAD+ uniquely targets nuclear/cytoplasmic enzymes (sirtuins, PARPs) affecting gene expression and DNA repair
- AOD-9604 targets lipolytic pathways through a mechanism still being fully elucidated, possibly involving the FAT/CD36 fatty acid transporter
4. Compound Deep Dives
4.1 Semaglutide — The Benchmark GLP-1 Receptor Agonist
Chemical Identity:
- CAS: 910463-68-2
- Molecular Weight: 4113.6 Da
- Sequence: H-His-Aib-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Val-Ser-Ser-Tyr-Leu-Glu-Gly-Gln-Ala-Ala-Lys(AEEA-AEEA-γ-Glu-octadecanedioic acid)-Glu-Phe-Ile-Ala-Trp-Leu-Val-Arg-Gly-Arg-Gly-OH
- Purity: ≥99% HPLC
Structural Basis of Extended Half-Life:
Semaglutide’s remarkable ~7-day research half-life arises from two key structural modifications to the native GLP-1(7-37) backbone:
-
Aib⁸ substitution (α-aminoisobutyric acid at position 8): Replaces the native Ala⁸ with a non-proteinogenic amino acid that is completely resistant to DPP-4 cleavage. DPP-4 specifically recognizes the N-terminal His⁷-Ala⁸ dipeptide; the Aib substitution renders this site unrecognizable while preserving GLP-1R binding affinity (PMID: 28102847).
-
C18 fatty diacid at Lys²⁶: A C18 octadecanedioic acid moiety is attached to Lys²⁶ via a γ-glutamic acid spacer and two 8-amino-3,6-dioxaoctanoic acid (AEEA) linker units. This fatty acid chain promotes reversible, high-affinity binding to serum albumin (Kd ~2 μM), dramatically reducing renal clearance and extending in vivo half-life to approximately 165 hours in humans.
-
94% sequence homology to native human GLP-1(7-37): Only 2 of 31 residues differ (Aib⁸ for Ala⁸; Arg³⁴ for Lys³⁴ in human GLP-1, plus the acylated Lys²⁶), preserving near-native receptor pharmacology.
Research-Relevant Pharmacological Properties:
| Property | Value | Significance for Research |
|---|---|---|
| GLP-1R affinity (Ki) | ~0.38 nM | High-affinity receptor binding enables robust signaling at low concentrations |
| GLP-1R selectivity | >10,000× vs. related receptors | Clean pharmacological signal with minimal off-target effects |
| Albumin binding (Kd) | ~2 μM | Sustained receptor exposure in albumin-containing media |
| DPP-4 resistance | Complete | Peptide remains intact in DPP-4-containing experimental systems |
| Solubility | >50 mg/mL at pH 7.4 | Flexible reconstitution for a range of experimental concentrations |
Available Research Formats (HKPEPTIDE WORLDWIDE):
| Format | SKU | Research Applications |
|---|---|---|
| Semaglutide 5 mg | HKPW-SEMA-5MG | Low-dose GLP-1R dose-response studies |
| Semaglutide 10 mg | HKPW-SEMA-10MG | Standard GLP-1R pharmacological characterization |
| Semaglutide 15 mg | HKPW-SEMA-15MG | Intermediate-dose metabolic pathway analysis |
| Semaglutide 20 mg | HKPW-SEMA-20MG | Extended in vitro receptor binding kinetics |
| Semaglutide 30 mg | HKPW-SEMA-30MG | Sustained GLP-1R signaling studies |
| Semaglutide 40 mg | HKPW-SEMA-40MG | High-dose receptor desensitization studies |
| Semaglutide 50 mg | HKPW-SEMA-50MG | Bulk quantitative pharmacology |
| Semaglutide 60 mg | HKPW-SEMA-60MG | Large-scale in vitro metabolic assays |
4.2 Tirzepatide — Dual Incretin Receptor Agonism
Chemical Identity:
- Molecular Weight: ~4800 Da
- Purity: ≥99% HPLC
Mechanism — Unbalanced Dual Agonism:
Tirzepatide is a 39-amino acid synthetic peptide that functions as a dual agonist at both the GIP receptor (GIPR) and GLP-1 receptor (GLP-1R), with a biased activity profile favoring GIPR. In cAMP accumulation assays using HEK293 cells expressing human receptors, Tirzepatide demonstrates approximately 5-fold higher potency at GIPR compared to GLP-1R (PMID: 34170647).
The rationale for dual agonism is rooted in the physiological synergy between GIP and GLP-1 signaling:
- GIP enhances insulin secretion (particularly in the fed state), promotes lipid buffering in white adipose tissue, and may improve insulin sensitivity through adipocyte signaling
- GLP-1 suppresses glucagon, slows gastric emptying, promotes satiety, and enhances glucose-dependent insulin secretion
- Together, the combined incretin effect exceeds what either pathway can achieve alone
Tirzepatide’s structure includes a C20 fatty diacid moiety for albumin binding (extending half-life to approximately 5 days), DPP-4-resistant modifications at the N-terminus, and an amino acid sequence engineered for balanced, sustained receptor activation at both targets.
GIP/GLP-1 Activity Ratio:
Research demonstrates that Tirzepatide’s GIP:GLP-1 potency ratio is approximately 5:1, meaning it is roughly 5 times more potent at GIPR than GLP-1R in standardized cAMP assays. This “GIP-biased” profile is intentional — the GIP component is thought to contribute to the enhanced body weight effects observed in clinical research, potentially through improved adipocyte function and insulin sensitization.
Key Research Distinction — Tirzepatide vs. Semaglutide:
| Parameter | Tirzepatide | Semaglutide |
|---|---|---|
| Receptor targets | GIPR + GLP-1R | GLP-1R only |
| GLP-1R potency | Lower than at GIPR | High (selective) |
| GIPR potency | High (primary) | None |
| Weight effects (research models) | Greater than GLP-1RA alone | Standard GLP-1RA benchmark |
| Half-life | ~5 days | ~7 days |
| MW | ~4800 Da | ~4113.6 Da |
Available Research Formats (HKPEPTIDE WORLDWIDE):
| Format | SKU |
|---|---|
| Tirzepatide 5 mg | HKPW-TIRZ-5MG |
| Tirzepatide 10 mg | HKPW-TIRZ-10MG |
| Tirzepatide 15 mg | HKPW-TIRZ-15MG |
| Tirzepatide 20 mg | HKPW-TIRZ-20MG |
| Tirzepatide 30 mg | HKPW-TIRZ-30MG |
| Tirzepatide 40 mg | HKPW-TIRZ-40MG |
| Tirzepatide 50 mg | HKPW-TIRZ-50MG |
| Tirzepatide 60 mg | HKPW-TIRZ-60MG |
4.3 Retatrutide — The Triple Agonist Frontier
Chemical Identity:
- Molecular Weight: ~5000 Da
- Purity: ≥99% HPLC
Mechanism — Balanced Triple Receptor Agonism:
Retatrutide (LY3437943) represents the current frontier of incretin pharmacology — a single peptide engineered to activate three distinct class B GPCRs: GIPR, GLP-1R, and GCGR (glucagon receptor). This triple agonism approach is based on the hypothesis that adding GCGR-mediated energy expenditure to GIP/GLP-1-mediated appetite suppression and insulin sensitization will produce superior metabolic outcomes (PMID: 37455222).
The glucagon receptor component is particularly intriguing from a research perspective. While glucagon is classically known as a hyperglycemic hormone (promoting hepatic glucose production), its effects on energy expenditure — through increased thermogenesis, lipolysis, and fatty acid oxidation — have been recognized since the 1950s. The key challenge was designing a peptide that activates GCGR sufficiently to enhance energy expenditure without producing clinically significant hyperglycemia — a challenge Retatrutide appears to address through balanced GIP/GLP-1 counter-regulation of the GCGR-mediated hepatic glucose output.
Receptor Activity Profile:
| Receptor | Activity | Functional Consequence |
|---|---|---|
| GIPR | Agonist | Insulin secretion ↑, adipocyte function ↑, insulin sensitivity ↑ |
| GLP-1R | Agonist | Insulin secretion ↑, glucagon ↓, gastric emptying ↓, satiety ↑ |
| GCGR | Agonist | Energy expenditure ↑, lipolysis ↑, fatty acid oxidation ↑ (counterbalanced by GLP-1R-mediated effects on hepatic glucose output) |
Research Significance:
Retatrutide enables researchers to investigate:
- The contribution of GCGR signaling to energy balance independently of food intake
- The interplay between GLP-1R-mediated glucose lowering and GCGR-mediated hepatic glucose production
- Whether triple agonism produces effects on body composition, lipid metabolism, and energy expenditure that exceed dual agonism
- The tissue-specific signaling bias of a single peptide activating three distinct receptors
Available Research Formats (HKPEPTIDE WORLDWIDE):
| Format | SKU |
|---|---|
| Retatrutide 5 mg | HKPW-RETA-5MG |
| Retatrutide 10 mg | HKPW-RETA-10MG |
| Retatrutide 15 mg | HKPW-RETA-15MG |
| Retatrutide 20 mg | HKPW-RETA-20MG |
| Retatrutide 30 mg | HKPW-RETA-30MG |
| Retatrutide 40 mg | HKPW-RETA-40MG |
| Retatrutide 50 mg | HKPW-RETA-50MG |
| Retatrutide 60 mg | HKPW-RETA-60MG |
4.4 Cagrilintide — Amylin Analog Research
Chemical Identity:
- Purity: ≥99% HPLC
Mechanism — Long-Acting Amylin Receptor Agonism:
Cagrilintide is an engineered long-acting analog of amylin (islet amyloid polypeptide, IAPP), a 37-amino acid hormone co-secreted with insulin from pancreatic β-cells. Native amylin has a short half-life and tends to aggregate into amyloid fibrils — both properties that are overcome by Cagrilintide’s structural modifications, which include amino acid substitutions that prevent aggregation while preserving receptor activation, and a fatty acid acylation for albumin binding that extends half-life to approximately 7–10 days.
Amylin receptors are heterodimers of the calcitonin receptor (CTR) with receptor activity-modifying proteins (RAMPs). Three subtypes exist:
- AMY1: CTR + RAMP1 (predominantly in hindbrain area postrema)
- AMY2: CTR + RAMP2
- AMY3: CTR + RAMP3
Cagrilintide activates all three subtypes, with hindbrain AMY1 activation being particularly important for satiety and gastric emptying effects. The area postrema — a circumventricular organ lacking a blood-brain barrier — is a key site of amylin action, where AMY1 receptor activation triggers neuronal signaling that reduces food intake and slows gastric emptying.
Cagrilintide/Semaglutide Combination (Cag/Sema Blend):
The combination of Cagrilintide (amylin analog) with Semaglutide (GLP-1RA) represents a mechanistically orthogonal approach to metabolic research:
- Independent receptor systems: AMY1-3 vs. GLP-1R — no receptor-level competition or cross-desensitization
- Independent signaling cascades: Calcitonin receptor/RAMP signaling vs. Gs-coupled GLP-1R/cAMP signaling
- Convergent physiological endpoints: Both reduce food intake, slow gastric emptying, and suppress glucagon through distinct neuronal and hormonal pathways
Available Research Formats (HKPEPTIDE WORLDWIDE):
| Format | SKU |
|---|---|
| Cagrilintide 5 mg | HKPW-CAGRI-5MG |
| Cagrilintide 10 mg | HKPW-CAGRI-10MG |
| Cagrilintide 5mg / Semaglutide 10mg Blend | HKPW-CAGSEMA-5-10MG |
4.5 AOD-9604 — Targeted Lipolytic Research
Chemical Identity:
- Molecular Weight: ~1800 Da
- Purity: ≥99% HPLC
Mechanism:
AOD-9604 (Advanced Obesity Drug-9604) is the synthetic hGH fragment encompassing amino acids 177-191 of the human growth hormone sequence. Research in the late 1990s and early 2000s demonstrated that this C-terminal fragment retains the lipolytic (fat-mobilizing) properties of full-length hGH while lacking its diabetogenic effects — specifically, AOD-9604 does not elevate blood glucose or induce insulin resistance, which are known effects of intact growth hormone (PMID: 11409885).
The precise receptor mediating AOD-9604’s lipolytic effects remains an active area of investigation. The leading hypothesis involves the FAT/CD36 fatty acid transporter/scavenger receptor, which is highly expressed in adipose tissue and plays roles in fatty acid uptake and lipid signaling. Unlike full-length hGH, AOD-9604 does not activate the growth hormone receptor (GHR) and therefore does not stimulate IGF-1 production — this explains the absence of diabetogenic effects.
Research Distinction — AOD-9604 vs. hGH:
| Parameter | AOD-9604 | Full-Length hGH |
|---|---|---|
| Target | Lipolytic pathway (FAT/CD36?) | GHR → JAK/STAT → IGF-1 |
| Lipolytic activity | Yes | Yes |
| IGF-1 elevation | No | Yes |
| Insulin resistance | No | Yes (via GH-induced lipolysis + IGF-1) |
| Half-life | ~4–6 hours | ~3–4 hours (recombinant) |
Available Research Formats (HKPEPTIDE WORLDWIDE):
| Format | SKU |
|---|---|
| AOD-9604 5 mg | HKPW-AOD-5MG |
| AOD-9604 10 mg | HKPW-AOD-10MG |
4.6 AICAR — AMPK Activation for Metabolic Research
Chemical Identity:
- CAS: 2627-69-2
- Molecular Weight: 258.2 Da
- Purity: ≥98% HPLC
Mechanism:
AICAR (5-aminoimidazole-4-carboxamide ribonucleoside) is a cell-permeable adenosine analog that serves as the classical pharmacological activator of AMP-activated protein kinase (AMPK). Upon cellular uptake, AICAR is phosphorylated by adenosine kinase to form ZMP (AICAR monophosphate), which mimics the effects of AMP — the natural allosteric activator of AMPK (PMID: 10383393).
ZMP binds to the γ-subunit of AMPK at the same site as AMP, inducing a conformational change that:
- Promotes phosphorylation of Thr172 on the α-subunit by upstream kinases (LKB1, CaMKKβ)
- Inhibits dephosphorylation of Thr172 by protein phosphatases
- Allosterically activates the phosphorylated enzyme
The result is robust activation of AMPK signaling, triggering:
- ↑ Glucose uptake: Through GLUT4 translocation (in insulin-sensitive tissues)
- ↑ Fatty acid oxidation: Through ACC2 phosphorylation and malonyl-CoA reduction
- ↑ Mitochondrial biogenesis: Through PGC-1α activation
- ↓ Lipogenesis: Through ACC1 phosphorylation
- ↓ Gluconeogenesis: Through CRTC2 and FOXO1 phosphorylation
Key Research Applications:
AICAR is widely used as an “exercise mimetic” in metabolic research because AMPK activation is one of the central metabolic responses to exercise. This makes AICAR valuable for:
- Studying exercise-like metabolic adaptations without the confounding variables of muscle contraction
- Investigating AMPK’s role in autophagy, mitochondrial quality control, and cellular stress resistance
- Characterizing metabolic flexibility — the ability to switch between glucose and fatty acid oxidation
Available Research Formats (HKPEPTIDE WORLDWIDE):
| Format | SKU |
|---|---|
| AICAR 5 mg | HKPW-AICAR-5MG |
| AICAR 50 mg | HKPW-AICAR-50MG |
4.7 MOTS-c — Mitochondrial-Nuclear Metabolic Signaling
Chemical Identity:
- Molecular Weight: 2174.6 Da
- Sequence: Met-Arg-Trp-Gln-Glu-Met-Gly-Tyr-Ile-Phe-Tyr-Pro-Arg-Lys-Leu-Arg
- Purity: ≥98% HPLC
Mechanism — A Novel Mitochondrial-Nuclear Communication Pathway:
MOTS-c (Mitochondrial Open Reading Frame of the 12S rRNA-c) was discovered in 2015 and represents a paradigm-shifting addition to metabolic peptide research. Unlike nuclear-encoded peptides, MOTS-c is translated within mitochondria from the 12S rRNA gene, making it one of the few known mitochondrial-derived peptides (MDPs) that function as systemic metabolic regulators (PMID: 25738459).
Under conditions of metabolic stress, MOTS-c translocates from mitochondria to the nucleus through a process that requires AMPK activation and involves the nuclear pore complex. Once in the nucleus, MOTS-c binds to antioxidant response elements (AREs) in the promoter regions of target genes, directly regulating their transcription. Key target pathways include:
- Folate-methionine cycle: MOTS-c increases expression of MTHFR and methionine synthase
- De novo purine biosynthesis: Increases expression of enzymes in the purine synthesis pathway
- AMPK signaling: MOTS-c itself activates AMPK, creating a feed-forward loop
The net effect is enhanced insulin sensitivity, increased fatty acid oxidation, and improved metabolic flexibility — effects that complement and extend beyond those achieved with GLP-1 receptor agonists or AMPK activators alone (PMID: 33417066).
MOTS-c vs. Other Metabolic Modulators:
| Parameter | MOTS-c | Semaglutide | AICAR |
|---|---|---|---|
| Origin | Mitochondrial-encoded | Synthetic GLP-1 analog | Synthetic adenosine analog |
| Primary target | Nuclear AREs (gene regulation) | GLP-1R (cell surface GPCR) | AMPK (intracellular kinase) |
| Timeframe | Hours (transcriptional) | Days (sustained GPCR) | Minutes-hours (kinase cascade) |
| Unique feature | Mitochondrial-nuclear crosstalk | Incretin physiology | Exercise mimetic |
Available Research Formats (HKPEPTIDE WORLDWIDE):
| Format | SKU |
|---|---|
| MOTS-c 10 mg | HKPW-MOTSC-10MG |
| MOTS-c 20 mg | HKPW-MOTSC-20MG |
| MOTS-c 30 mg | HKPW-MOTSC-30MG |
| MOTS-c 40 mg | HKPW-MOTSC-40MG |
4.8 NAD+ — Cellular Metabolism and Sirtuin Biology
Chemical Identity:
- Molecular Weight: 663.4 Da
- Purity: ≥98% HPLC
Mechanism — The Central Metabolic Coenzyme:
Nicotinamide Adenine Dinucleotide (NAD+) is arguably the most fundamental molecule in cellular metabolism. It serves two essential roles:
-
Redox coenzyme: NAD+ accepts electrons during glycolysis, fatty acid oxidation, and the TCA cycle, forming NADH. NADH then donates electrons to Complex I of the electron transport chain, driving mitochondrial ATP production. The NAD+/NADH ratio is a key indicator of cellular redox status.
-
Enzyme substrate: NAD+ is consumed as a substrate by three major enzyme families:
- Sirtuins (SIRT1-7): NAD+-dependent deacetylases that regulate metabolism, stress resistance, and longevity. SIRT1 deacetylates PGC-1α (mitochondrial biogenesis), FOXO transcription factors (stress resistance), and p53 (cell survival). SIRT3 is the primary mitochondrial sirtuin, regulating fatty acid oxidation, ketone body production, and antioxidant defense.
- PARPs (Poly-ADP-Ribose Polymerases): NAD+-consuming enzymes involved in DNA repair. PARP1 activation following DNA damage can deplete cellular NAD+ pools.
- CD38: A NAD+ glycohydrolase on immune cells that consumes NAD+ — CD38 activity increases with age, contributing to age-related NAD+ decline.
NAD+ Decline and Metabolic Research:
NAD+ levels decline with age across multiple tissues (30–50% reduction between ages 40–60), correlating with mitochondrial dysfunction, impaired metabolic flexibility, and reduced stress resistance. This observation has driven extensive research into NAD+ repletion strategies, including NAD+ precursors (nicotinamide riboside, nicotinamide mononucleotide) and direct NAD+ supplementation (PMID: 32668227, PMID: 27304511).
NAD+ and Peptide Research Synergies:
The intersection of NAD+ biology with peptide metabolic modulators creates rich research opportunities:
- GLP-1R agonists + NAD+: GLP-1R activation increases SIRT1 expression in some tissues; NAD+ availability may potentiate this effect
- MOTS-c + NAD+: MOTS-c’s effects on the folate-methionine cycle influence NAD+ biosynthesis; NAD+ repletion may enhance MOTS-c-mediated gene regulation
- SS-31 + NAD+: SS-31’s mitochondrial protective effects combined with NAD+-mediated sirtuin activation may produce complementary mitochondrial benefits
Available Research Formats (HKPEPTIDE WORLDWIDE):
| Format | SKU |
|---|---|
| NAD+ 100 mg | HKPW-NAD-100MG |
| NAD+ 500 mg | HKPW-NAD-500MG |
| NAD+ 1000 mg | HKPW-NAD-1000MG |
5. Comparative Research Protocol Design
5.1 Selecting the Right Compound for Your Research Question
The choice of metabolic research compound depends critically on the specific research question:
| Research Question | Recommended Compound(s) | Rationale |
|---|---|---|
| Characterizing GLP-1R signaling | Semaglutide | Clean, well-characterized selective GLP-1R agonist |
| Comparing single vs. dual incretin agonism | Tirzepatide vs. Semaglutide | Direct comparison of dual (GIP/GLP-1) vs. single (GLP-1) agonism |
| Investigating glucagon receptor contribution | Retatrutide vs. Tirzepatide | Adding GCGR to GIP/GLP-1 dual agonism |
| Amylin-mediated satiety mechanisms | Cagrilintide | Selective amylin receptor activation without incretin effects |
| Orthogonal pathway combination | Cag/Sema Blend | Independent amylin + GLP-1R pathways |
| Lipolysis without GH effects | AOD-9604 | hGH fragment with selective lipolytic activity |
| AMPK signaling characterization | AICAR | Classical pharmacological AMPK activator |
| Mitochondrial-nuclear communication | MOTS-c | Unique mitochondrial-derived signaling peptide |
| Sirtuin biology / NAD+ metabolism | NAD+ | Central metabolic coenzyme and sirtuin substrate |
5.2 Concentration and Dose-Response Considerations
For in vitro research, the following typical concentration ranges are used as starting points for dose-response characterization:
| Compound | In Vitro Range | Key Considerations |
|---|---|---|
| Semaglutide | 0.01–100 nM | For GLP-1R cAMP assays; albumin-containing media extends effective concentration |
| Tirzepatide | 0.01–100 nM | Consider GIPR:GLP-1R expression ratio in cell model |
| Retatrutide | 0.01–100 nM | Requires cells expressing all three receptors for full characterization |
| Cagrilintide | 0.1–1000 nM | Requires CTR/RAMP co-expression for functional amylin receptors |
| AOD-9604 | 0.1–100 µM | Higher concentrations typically needed than incretin peptides |
| AICAR | 100–2000 µM | mM range for robust AMPK activation in most cell types |
| MOTS-c | 1–100 µM | Requires sufficient incubation time for nuclear translocation |
| NAD+ | 10–1000 µM | Consider cell permeability and NAD+ transporter expression |
5.3 Combinatorial Protocol Design
Rational combinations for multi-compound research protocols:
- Incretin + Amylin: Semaglutide + Cagrilintide for orthogonal satiety/gastric emptying pathway investigation
- Incretin + AMPK: Semaglutide + AICAR to study receptor-mediated vs. intracellular energy sensing
- Incretin + Mitochondrial: Tirzepatide + MOTS-c to compare GPCR-mediated vs. mitochondrial-nuclear metabolic signaling
- Triple Agonist + NAD+: Retatrutide + NAD+ for combined receptor pharmacology and sirtuin activation
- AMPK + NAD+: AICAR + NAD+ for energy sensing and sirtuin pathway synergy
6. Frequently Asked Questions
6.1 What is the difference between Semaglutide, Tirzepatide, and Retatrutide?
Semaglutide is a selective GLP-1 receptor agonist with 94% homology to native GLP-1 and a ~7-day half-life achieved through albumin binding. Tirzepatide is a dual GIP/GLP-1 receptor agonist with a GIP-biased activity profile (~5:1 GIP:GLP-1 potency ratio), providing enhanced metabolic effects through simultaneous activation of both incretin receptors. Retatrutide is a triple agonist targeting GIPR, GLP-1R, and GCGR (glucagon receptor), adding glucagon-mediated energy expenditure to the incretin effects. Each represents a progressive increase in receptor coverage: single → dual → triple agonism, enabling increasingly comprehensive metabolic pathway modulation in research settings.
6.2 How does Cagrilintide complement GLP-1 receptor agonists?
Cagrilintide is a long-acting amylin analog that activates amylin receptors (AMY1-3, which are CTR/RAMP complexes), producing complementary metabolic effects through a mechanism completely independent of GLP-1R agonism. While GLP-1R agonists enhance glucose-dependent insulin secretion, suppress glucagon, and slow gastric emptying through GLP-1R/Gs/cAMP signaling, amylin receptor activation works through hindbrain area postrema signaling to suppress postprandial glucagon, delay gastric emptying, and promote satiety. The Cag/Sema combination leverages these independent receptor systems for amplified metabolic research outcomes without receptor-level competition.
6.3 What is the role of mitochondrial peptides in metabolic research?
Mitochondrial peptides like MOTS-c operate at the intersection of cellular energetics and systemic metabolism through mechanisms distinct from cell-surface receptor agonists. MOTS-c is a 16-amino acid peptide encoded within the mitochondrial 12S rRNA that translocates to the nucleus under metabolic stress, where it directly regulates the expression of nuclear-encoded metabolic genes involved in the folate-methionine cycle and de novo purine biosynthesis. This mitochondrial-nuclear communication pathway represents a fundamentally different regulatory paradigm from GPCR-mediated incretin signaling and offers complementary research tools for studying metabolic homeostasis.
6.4 How does AOD-9604 differ from growth hormone in metabolic research?
AOD-9604 (hGH 177-191) is the C-terminal fragment of human growth hormone that retains the lipolytic (fat-mobilizing) properties of full-length hGH without activating the growth hormone receptor. This means AOD-9604 promotes fat breakdown without stimulating IGF-1 production or inducing the insulin resistance associated with full-length GH. This selectivity makes AOD-9604 a valuable research tool for isolating lipolytic pathways from broader somatotropic effects, enabling targeted investigation of fat metabolism mechanisms.
6.5 Why is NAD+ research relevant to metabolic peptide studies?
NAD+ is the central coenzyme linking cellular redox status to sirtuin-mediated metabolic regulation. Sirtuins (SIRT1-7) are NAD+-dependent deacetylases that regulate mitochondrial biogenesis (via PGC-1α), fatty acid oxidation (via SIRT3), and insulin sensitivity — the same metabolic pathways targeted by GLP-1 agonists and mitochondrial peptides. NAD+ levels decline 30–50% with aging, and this decline is implicated in age-related metabolic dysfunction. Research combining NAD+ repletion with incretin agonism or mitochondrial peptide signaling enables investigation of whether sirtuin activity limits or enhances peptide-mediated metabolic effects.
7. Cluster Link Grid — GLP-1/Metabolic Resource Directory
Related Pillar Hub Pages
| Pillar | Description | Link |
|---|---|---|
| Complete Guide to Research Peptides | Master classification of all peptide categories | Complete Guide |
| Peptide Quality Verification Hub | COA, HPLC, quality standards for metabolic peptides | Quality Hub |
| Healing & Regenerative Peptides Hub | Tissue repair (metabolic-tissue crosstalk) | Healing Hub |
GLP-1/Metabolic Blog Articles
| Article | Focus | Link |
|---|---|---|
| GLP-1 Peptides and Metabolic Research | Foundational GLP-1 overview | /blog/glp-1-peptides-metabolic-research.md |
| GLP-1 Peptides — Exploring the Future of Scientific Innovation | Forward-looking GLP-1 analysis | /blog/glp-1-peptides-and-metabolic-research-exploring-the-future-of-scientific-innovat.md |
| Peptides in Skincare and Weight Loss Research | Metabolic-cosmetic peptide crosstalk | /blog/peptides-in-skincare-and-weight-loss-research.md |
| Why Muscle Growth Peptide Research Is Expanding | GH/metabolic overlap | /blog/why-muscle-growth-peptide-research-is-expanding.md |
| The Growing Interest in Peptides for Muscle Research | Muscle-metabolism interface | /blog/the-growing-interest-in-peptides-for-muscle-research.md |
| Why Anti-Aging Peptide Research Is Growing Rapidly | NAD+, mitochondrial peptides in aging | /blog/why-anti-aging-peptide-research-is-growing-rapidly.md |
| Research Peptides Guide | Comprehensive peptide overview | /blog/research-peptides-guide.md |
Semaglutide Products
| Product | Key Specs | Link |
|---|---|---|
| Semaglutide 5 mg | ≥99% HPLC, GLP-1RA | /products/semaglutide-5-mg-research-peptide-usa.md |
| Semaglutide 10 mg | ≥99% HPLC, CAS 910463-68-2, MW 4113.6 Da | /products/semaglutide-10-mg-grade-glp-1-research-peptide.md |
| Semaglutide 15 mg | ≥99% HPLC | /products/semaglutide-15-mg-research-peptide-usa.md |
| Semaglutide 20 mg | ≥99% HPLC | /products/semaglutide-20-mg-high-purity-peptide.md |
| Semaglutide 30 mg | ≥99% HPLC | /products/semaglutide-30-mg-research-grade-glp-1-peptide.md |
| Semaglutide 40 mg | ≥99% HPLC | /products/semaglutide-40-mg-glp-1-research-peptide-usa.md |
| Semaglutide 50 mg | ≥99% HPLC | /products/semaglutide-50-mg-research-peptide-usa.md |
| Semaglutide 60 mg | ≥99% HPLC | /products/semaglutide-60-mg-research-peptide-usa-supply.md |
Tirzepatide Products
| Product | Key Specs | Link |
|---|---|---|
| Tirzepatide 5 mg | ≥99% HPLC, Dual GIP/GLP-1RA | /products/tirzepatide-5-mg-research-peptide-usa.md |
| Tirzepatide 10 mg | ≥99% HPLC | /products/tirzepatide-10-mg-research-peptide-vials-usa.md |
| Tirzepatide 15 mg | ≥99% HPLC | /products/tirzepatide-15mg-high-purity-research-peptide.md |
| Tirzepatide 20 mg | ≥99% HPLC | /products/tirzepatide-20mg-metabolic-research-peptide.md |
| Tirzepatide 30 mg | ≥99% HPLC | /products/tirzepatide-30-mg-research-peptide-usa.md |
| Tirzepatide 40 mg | ≥99% HPLC | /products/tirzepatide-40mg-bulk-sales-usa.md |
| Tirzepatide 50 mg | ≥99% HPLC | /products/high-purity-tirzepatide-50mg.md |
| Tirzepatide 60 mg | ≥99% HPLC | /products/tirzepatide-60-mg-lap-tested-usa.md |
Retatrutide Products
| Product | Key Specs | Link |
|---|---|---|
| Retatrutide 5 mg | ≥99% HPLC, Triple GIP/GLP-1R/GCGR | /products/retatrutide-5-mg-scientific-research-materials.md |
| Retatrutide 10 mg | ≥99% HPLC | /products/retatrutide-10-mg-scientific-research-materials.md |
| Retatrutide 15 mg | ≥99% HPLC | /products/retatrutide-15-mg-laboratory-peptide-supply.md |
| Retatrutide 20 mg | ≥99% HPLC | /products/retatrutide-20-mg-high-purity-peptides.md |
| Retatrutide 30 mg | ≥99% HPLC | /products/retatrutide-30-mg-research-peptides-usa.md |
| Retatrutide 40 mg | ≥99% HPLC | /products/retatrutide-40-mg-lab-grade-peptides.md |
| Retatrutide 50 mg | ≥99% HPLC | /products/retatrutide-50-mg.md |
| Retatrutide 60 mg | ≥99% HPLC | /products/retatrutide-60-mg-research-peptide.md |
Cagrilintide & Amylin Products
| Product | Key Specs | Link |
|---|---|---|
| Cagrilintide 5 mg | ≥99% HPLC, Long-acting amylin analog | /products/cagrilintide-5-mg-amylin-research-peptide-usa.md |
| Cagrilintide 10 mg | ≥99% HPLC | /products/cagrilintide-10-mg-amylin-analog-research-peptide-usa.md |
| Cagrilintide 5mg/Semaglutide 10mg Blend | ≥99% HPLC, Dual amylin + GLP-1RA | /products/cagrilintide-5-mg-semaglutide-10-mg-research-peptide-blend.md |
Other Metabolic Compounds
| Product | Key Specs | Link |
|---|---|---|
| AOD-9604 5 mg | ≥99% HPLC, hGH 177-191 fragment | /products/aod9604-5-mg-fragmented-hgh-research-peptide-usa.md |
| AOD-9604 10 mg | ≥99% HPLC | /products/aod9604-10-mg-research-peptide-usa.md |
| AICAR 5 mg | ≥98% HPLC, AMPK activator | /products/aicar-5-mg-research-compound-usa.md |
| AICAR 50 mg | ≥98% HPLC | /products/aicar-50-mg-research-compound-usa.md |
| MOTS-c 10 mg | ≥98% HPLC, Mitochondrial peptide | /products/mots-c-10-mg-mitochondrial-peptide-supply-usa.md |
| MOTS-c 20 mg | ≥98% HPLC | /products/mots-c-20-mg-mitochondrial-peptide-research-usa.md |
| MOTS-c 30 mg | ≥98% HPLC | /products/mots-c-30-mg-mitochondrial-derived-research-peptide-usa.md |
| MOTS-c 40 mg | ≥98% HPLC | /products/mots-c-40-mg-mitochondrial-peptide-research-usa.md |
| NAD+ 100 mg | ≥98% HPLC | /products/nad-e2-81-ba-100-mg-research-compound-usa.md |
| NAD+ 500 mg | ≥98% HPLC | /products/nad-e2-81-ba-500-mg-cellular-metabolism-research-usa.md |
| NAD+ 1000 mg | ≥98% HPLC | /products/nad-e2-81-ba-1000-mg-laboratory-research-compound-usa.md |
Mitochondrial Peptides (Additional)
| Product | Key Specs | Link |
|---|---|---|
| SS-31 5 mg | ≥98% HPLC, Cardiolipin-targeted tetrapeptide | /products/buy-ss-31-5-mg-research-peptide-usa.md |
| SS-31 10 mg | ≥98% HPLC | /products/ss-31-10-mg-precision-mitochondrial-research-peptide-usa.md |
| SS-31 15 mg | ≥98% HPLC | /products/ss-31-15-mg-precision-mitochondrial-research-peptide-usa.md |
| SS-31 30 mg | ≥98% HPLC | /products/ss-31-30-mg-mitochondrial-research-peptide-usa.md |
8. References
- Lau J, Bloch P, Schäffer L, et al. Discovery of the once-weekly glucagon-like peptide-1 (GLP-1) analogue semaglutide. J Med Chem. 2015;58(18):7370-7380. PMID: 28102847.
- Frías JP, Davies MJ, Rosenstock J, et al. Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes. N Engl J Med. 2021;385(6):503-515. PMID: 34170647.
- Jastreboff AM, Kaplan LM, Frías JP, et al. Triple-hormone-receptor agonist retatrutide for obesity — a phase 2 trial. N Engl J Med. 2023;389(6):514-526. PMID: 37455222.
- Holst JJ. The physiology of glucagon-like peptide 1. Physiol Rev. 2007;87(4):1409-1439. PMID: 17928588.
- Lee C, Zeng J, Drew BG, et al. The mitochondrial-derived peptide MOTS-c promotes metabolic homeostasis and reduces obesity and insulin resistance. Cell Metab. 2015;21(3):443-454. PMID: 25738459.
- Kim TY, Kim KH, Cheong JH, Lee C. MOTS-c: A novel mitochondrial-derived peptide regulating metabolism. Trends Endocrinol Metab. 2021;32(4):233-246. PMID: 33417066.
- Corton JM, Gillespie JG, Hawley SA, Hardie DG. 5-aminoimidazole-4-carboxamide ribonucleoside. A specific method for activating AMP-activated protein kinase in intact cells? Eur J Biochem. 1995;229(2):558-565. PMID: 10383393.
- Ng FM, Sun J, Sharma L, Libinaki R, Jiang WJ. Metabolic studies of a synthetic lipolytic domain (AOD9604) of human growth hormone. Diabetes Obes Metab. 2001;3(2):139-150. PMID: 11409885.
- Rajman L, Chwalek K, Sinclair DA. Therapeutic potential of NAD-boosting molecules: the in vivo evidence. Cell Metab. 2018;27(3):529-547. PMID: 32668227.
- Verdin E. NAD⁺ in aging, metabolism, and neurodegeneration. Science. 2015;350(6265):1208-1213. PMID: 27304511.
- Szeto HH, Birk AV. Serendipity and the discovery of novel compounds that restore mitochondrial plasticity. Clin Pharmacol Ther. 2014;96(6):672-683. PMID: 26586186.
- Birk AV, Liu S, Soong Y, et al. The mitochondrial-targeted compound SS-31 re-energizes ischemic mitochondria by interacting with cardiolipin. J Am Soc Nephrol. 2013;24(8):1250-1261. PMID: 26846575.
- Hay DL, Chen S, Lutz TA, et al. Amylin: pharmacology, physiology, and clinical potential. Pharmacol Rev. 2015;67(3):564-600. PMID: 26071095.
- Baggio LL, Drucker DJ. Biology of incretins: GLP-1 and GIP. Gastroenterology. 2007;132(6):2131-2157. PMID: 17498508.
- Hardie DG, Ross FA, Hawley SA. AMPK: a nutrient and energy sensor that maintains energy homeostasis. Nat Rev Mol Cell Biol. 2012;13(4):251-262. PMID: 22436748.
This pillar hub was last reviewed by the HKPEPTIDE WORLDWIDE Research Team on 2026-08-08. All product listings are for laboratory research purposes only. Always consult your institution’s research compliance office and biosafety committee before initiating new research protocols. For the most current product availability, COA documentation, and technical specifications, visit hkpeptidesworldwide.com.